Merck & Co., Inc. v. Teva Pharmaceuticals Usa, Inc.
Merck & Co., Inc. v. Teva Pharmaceuticals Usa, Inc.
Opinion of the Court
NEWMAN and LOURIE, Circuit Judges, would rehear the appeal en banc.
LOURIE, Circuit Judge, with whom MICHEL, Chief Judge, and PAULINE NEWMAN, Circuit Judge, join, dissents in a separate opinion.
did not participate in the vote.
ORDER
A combined petition for panel rehearing and rehearing en banc was filed by the Appellee, and a response thereto was invited by the court and filed by the Appellant.
Upon consideration thereof,
IT IS ORDERED THAT:
(1) The petition for panel rehearing is denied.
*1339 (2) The petition for rehearing én banc is denied.
(3) The mandate of the court will issue on April 28, 2005.
. An amicus curiae brief was filed by the Pharmaceutical Research and Manufacturers of America.
Dissenting Opinion
with whom MICHEL, Chief Judge, and PAULINE NEWMAN, Circuit Judge, join, dissenting from order denying rehearing en banc.
I respectfully dissent from the court’s declining to hear this case en banc. In my opinion, the panel erroneously concludes that commercial success is not probative because “others were legally barred” from commercially testing certain ideas in the prior art. Moreover, I believe the panel erred in linking commercial success to the failure of others.
Commercial success is a fact question, and, once it is established, as found here by the trial court, the only other question is whether the success is attributable to the claimed invention (“nexus”), rather than to other factors such as market power, advertising, demand for all products of a given type, a rising economy that “lifts all boats,” etc. It is not negatived by any inability of others to test various formulations because of the existence of another patent. Success is success. The panel’s rule is especially unsound in the context of an improvement patent, as here, because it holds in effect that commercial success for an improvement is irrelevant when a prior patent dominates the basic invention.
Commercial success is also independent of any “failure of others,” as that is another, separate secondary consideration.
Respectfully, the full court should have reheard the appeal to eliminate the confusion in the law that the panel opinion creates.
Reference
- Full Case Name
- MERCK & CO., INC., Plaintiff-Appellee, v. TEVA PHARMACEUTICALS USA, INC., Defendant-Appellant
- Cited By
- 3 cases
- Status
- Published